Teen with painful papules and plaques is diagnosed with Sweet's Syndrome
THE CASE
DIAGNOSIS:
Sweet's syndrome, also known as acute febrile neutrophilic dermatosis, is a reaction pattern in the skin characterized by a neutrophilic infiltrate. This may present in several forms, including:1
Classical Sweet's syndrome (CSS) is often preceded by a streptococcal or viral upper respiratory tract infection, and is occasionally associated with inflammatory bowel disease or pregnancy.
Malignancy-associated Sweet's syndrome (MASS) occurs in the context of a patient with an occult solid tumor or a hematologic dyscrasia, most commonly acute myeloid leukemia.
Drug-induced Sweet's syndrome (DISS) is most commonly triggered by granulocyte colony stimulating factor (GCSF) or the antibiotic sulfamethoxazole-trimethoprim.2,3
CLINICAL FINDINGS
DIFFERENTIAL DIAGNOSIS OF NODULAR RASH
Erythema nodosum is another reactive erythema that may also be triggered by infections, drugs, inflammatory diseases, lymphomas, and pregnancy. Deep-seated painful, erythematous to violaceous nodules develop typically on the anterior surface of both legs, and usually resolve in two to eight weeks without scarring. The eruption of Sweet's syndrome can be clinically and histologically distinguished from erythema nodosum, which is an inflammatory disorder involving fat.
Disseminated gonococcemia begins with papules and vesicles, which may occasionally evolve to pustules with a necrotic base. It may also be associated with fever and polyarthritis. A Gram stain obtained after unroofing a pustule reveals the organism.
Rheumatoid neutrophilic dermatitis (RND) occurs most frequently in women with seropositive rheumatoid arthritis (RA). The typical eruption consists of erythematous, urticarial-like papules, plaques or nodules less than two centimeters in diameter. Unlike Sweet's syndrome, lesions in RND usually clear with aggressive treatment of the RA. Moreover, these patients do not present with fever or other constitutional symptoms.
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Pz-cel granted FDA Priority Review to treat recessive dystrophic epidermolysis bullosa
November 28th 2023The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction.
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
IDP-126 topical gel approved by FDA to treat acne in patients 12 years and up
October 21st 2023The topical gel is the first and only FDA-approved triple-combination, fixed-dose topical treatment for acne, and is set to be available in the first quarter of 2024, according to Bausch Health Companies Inc.
A 13-year-old girl with well-demarcated rash on back and chest
October 19th 2023A healthy 13-year-old girl presented with a 1-month history of an asymptomatic, well-demarcated rash on her back and upper chest. The eruption consisted of discrete, dark brown papules that coalesced into large, flat-topped plaques with mild superficial scale and accentuation of skin markings. What's the diagnosis?